🇺🇸 FDA
Pipeline program

BPS804

MBPS208

Phase 2 small_molecule terminated

Quick answer

BPS804 for Osteogenesis Imperfecta is a Phase 2 program (small_molecule) at Mereo BioPharma Group plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Mereo BioPharma Group plc
Indication
Osteogenesis Imperfecta
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials